Home＞BUSINESS
Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med(Dec.28.2017)
Sumitomo Dainippon Pharma and France’s Poxel have launched a PIII clinical trial program in Japan for imeglimin, an investigational type 2 diabetes drug developed by the Merck Serono spinoff, with its filing eyed for 2020, the two companies said on December 27 ...
(LOG IN FOR FULL STORY)
- Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel Oct.10
- Poxel Forms Japan Outpost, Hitches Janssen’s Kaneko as Country Chief Sep.14
-
Poxel Eyeing Japan as 1st Market for Its Lead Diabetes Candidate: CEO
Feb.06
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel Nov.01
-
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand Oct.19
- Takeda Earns Japan Clearance for Shire Acquisition Oct.19
- Asahi Kasei Obtains Patent License for iPS Cell-Derived Cartilage Regeneration Technology Oct.18
- Sumitomo Dainippon to Invest in, Conduct Joint R&D with Cyborg Tech Startup Oct.18
- Nippon Shinyaku Seeks Japan Approval for Hepatic VOD Treatment Defibrotide Oct.18
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme(Oct.19)
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand(Oct.19)
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications(Oct.19)
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan(Oct.19)
- Takeda Earns Japan Clearance for Shire Acquisition(Oct.19)
